APCCC 2024: Should the Primary Be Treated in Synchronous High-Volume mHSPC
APCCC 2024 management of metastatic hormone sensitive prostate cancer (mHSPC), synchronous high-volume mHSPC, HORRAD trial, de novo mHSPC, STAMPEDE Arm H, STOPCAP collaboration.